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ABSTRACT
The Joint Commission in a joint effort with the Centers of Medicare and Medicaid
Services (CMS) has established certain “core measures” by which hospital performance is
measured. One of these is the measure for patients with ST-elevation myocardial infarction
(STEMI) recommending percutaneous coronary intervention within 90 minutes of presentation
to the Emergency Department in institutions that are able to provide this service. This
recommendation does not take into account the long-term use of clopidogrel that is
recommended by the American College of Cardiology and American Heart Association for
patients that are treated with coronary stents.
The purpose of this study was to evaluate outcomes of providing a short course of
clopidogrel versus a prescription alone for clopidogrel to uninsured patients experiencing STEMI
who were treated with a bare metal stent.
After conducting a cost-benefit analysis, a policy was approved that provided uninsured
STEMI patients with clopidogrel at discharge rather than a prescription. A social worker
evaluated patients to determine if they met criteria and arranged for medication delivery to the
patient’s bedside. A retrospective chart review for all patients who presented to the Emergency
Department during two different time frames (before and after policy implementation) was
conducted to evaluate if providing clopidogrel decreased readmissions. Data were collected on
over a 15-month period of time before and after the clopidogrel policy implementation to allow
for evaluation of 90-day readmissions with repeat STEMI. Data were analyzed using chi-square
cross tabulation and T-test for independent samples.
A total of 201 charts were reviewed: 100 from the pre-intervention group and 101 from
the post-intervention group. Demographic characteristics of age, gender and insurance status
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were not statistically different between groups. The mean age for the control group was 59.1 (+
13.8) years and 58.9 (+ 13.6) years for the intervention group. Twenty percent of the patients
were uninsured. Five uninsured patients were readmitted with STEMI prior to the intervention
compared to two patients in the intervention group (p = .191). The admissions for the preintervention patients occurred in the first 30 days after discharge compared to 31-60 days in the
post-intervention group. All of the patients who were readmitted were assessed to be
noncompliant with treatment. Additionally, a transition to increased use of bare metal stents in
STEMI patients from 23.1% pre-intervention to 67.4% post-intervention was noted (p < .001).
Although no differences were found in readmission rates, fewer readmissions for STEMI
were noted after the intervention. The small number of patients who were readmitted with
STEMI likely accounted for this finding, and additional monitoring of readmission rates is
warranted. Despite provision of the clopidogrel, adherence remains an issue and needs to be
addressed. During the intervention, physicians were encouraged to consider the financial and
social resources of individual STEMI patients presenting to the Emergency Department to help
identify patients that would be less likely to adhere to antiplatelet therapy. In those believed to
be at high risk for non-adherence, primarily due to inability to purchase the relatively expensive
medication clopidogrel, many physicians chose to insert bare metal stents rather than drugeluting stents to take advantage of the shorter course of clopidogrel required post procedure.
Provision of a 30-day course of clopidogrel and aspirin was a major part of this effort to decrease
recurrent myocardial infarction in this at-risk population. A few patients eligible for the
clopidogrel were not provided the medication if they were admitted to a nursing unit where staff
members were not familiar with the policy; revisions to the policy to ensure medication is
provided to all eligible patients will be made. Providing clopidogrel to patients who experience
iv

STEMI may improve adherence and thereby decrease readmissions as a result of repeat STEMI
due to subacute thrombus formation. Patients who experience STEMI continue to be vulnerable
after STEMI. Programs that provide medication to patients should be expanded within this
facility and to other hospital systems to encompass all patients who are treated for STEMI.
Multi-disciplinary collaboration is necessary in developing and implementing a program that will
address care for this.
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CHAPTER ONE: INTRODUCTION
In February 2006, a 581-bed tertiary care center in Central Florida initiated a Code
STEMI process to provide timely interventional care to patients presenting to the Emergency
Department (ED) with ST- segment elevation myocardial infarction (STEMI). In July 2006,
after approximately 50 patients had been treated using the Code STEMI process, a 55-year old,
female patient presented to the ED with signs and symptoms consistent with STEMI. She was
treated in a very timely manner using the same process. In this particular case, the physician had
determined that there was a potential for medication non-adherence and therefore treated her
with a bare metal stent (BMS). The patient had a successful outcome and was discharged home
after 2 days. Prior to discharge the patient was educated regarding the importance of medication
adherence and she reassured the physician and nurses that she understood and that she would
take her follow-up medications.
As was the hospital policy at the time, the patient was given a 7-day supply of
clopidogrel through the Social Work department. She was also referred to the County Medical
Clinic (CMC) for follow up. It was at this point that she ‘fell through the cracks’. The earliest
that the patient was able to schedule an appointment with the CMC was two weeks after the date
of discharge (actually a timely appointment). She took her medication as she was instructed, but
ran out of medication one week prior to her appointment and was unable to afford a refill. Once
she was seen by the CMC, she received more clopidogrel and began taking her medication as
prescribed. Unfortunately, in the one week that she did not take clopidogrel, she developed
subacute thrombosis in the previously placed stent and she returned to the ED with an more
serious STEMI the following evening. While she was again treated in a very timely manner, the
second STEMI resulted in complete embarrassment of her cardiac function and she required a
1

prolonged stay in the coronary care unit (CCU). While in the CCU, she required treatment with
balloon counterpulsation and nearly died. The second STEMI resulted in unnecessary suffering
for the patient and likely shortened her life.
This patient event was the impetus for designing a project based on the available
evidence for treating STEMI patients. The intent of this project is to help patients with
clopidogrel adherence and decrease the occurrence of subacute thrombosis.

Background
Coronary heart disease (CHD) is the killer of more Americans than any other single
disease. CHD includes acute myocardial infarction (AMI), acute coronary syndromes (ACS),
and angina pectoris. The American Heart Association (AHA) estimates that 565,000 new AMI’s
occur annually while there are about 300,000 occurrences of repeat AMI each year. In 2004,
157,559 people in the United States died as a result of an AMI (American Heart Association,
2007). AMI is identified using electrocardiography (ECG) and cardiac enzymes (CPK-MB and
troponins). STEMI is one type of AMI and is easily and quickly identified using ECG. This
tends to be the more immediately lethal form of AMI and resources to expedite care of these
patients presenting to healthcare facilities has been the focus of a world-wide initiative in recent
years.
A large volume of data shows early recognition and treatment of patients with STEMI
results in improved outcomes for these patients (Faxon, 2007). Options for treating patients with
AMI that present to the hospital typically have included percutaneous coronary intervention
(PCI), which includes balloon angioplasty and/or stent deployment, atherectomy, and
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thrombectomy; or the use of fibrinolytics. Our facility’s current practice is to facilitate emergent
coronary thrombectomy and stent placement in most cases.
The Joint Commission, in conjunction with the Centers for Medicare and Medicaid
Services (CMS), developed a set of measurable outcomes for certain disease states that each
accredited hospital in the United States (US) must measure and report. These diseases were
chosen based on prevalence and literature support that quality of care and outcomes could be
improved with consistent delivery of treatment. AMI is included in these measures (The Joint
Commission, Centers for Medicare and Medicaid Services, 2006).
The AMI core measure is made up of nine indicators. The two indicators that affect early
intervention of STEMI are AMI-7 and AMI 7a, median time to fibrinolysis, and fibrinolytic
therapy received within 30 minutes of arrival to hospital; and AMI-8 and AMI 8a, median time
to primary PCI and primary PCI received within 90 minutes of arrival to hospital. Because the
use of fibrinolytics has decreased due to the ease of access to interventional cardiac
catheterization labs and data that shows PCI received within 90 minutes for patients presenting to
the ED where primary PCI is performed or within 120 minutes for patients presenting to an ED
of a facility that does not provide PCI and requires transfer results in decreased mortality and
morbidity, this discussion focuses on indicators AMI 8 and AMI 8a.

Problem
Prior to the implementation of the The Joint Commission / CMS AMI indicators, a
patient was evaluated for PCI versus fibrinolytics based on financial status and ability and/or
willingness to be compliant with long-term medications. As treatment has trended towards early
PCI, it is important to recognize that when PCI involves stent deployment (which is common),
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continued medical treatment with clopidogrel is necessary to decrease the risk of subacute
thrombosis.
Subacute thrombosis is defined as partial or total stent occlusion in the initial stent as
documented by angiography (Iakovou, 2005). Antiplatelet agents (i.e. clopidogrel and aspirin)
decrease the risk of subacute thrombosis. The American College of Cardiology/American Heart
Association (ACC/AHA) recommend varying lengths of antiplatelet therapy based on the type of
stent that is placed. ACC/AHA recommends a minimum of 12 months of clopidogrel for
patients who receive a drug-eluting stent (DES) and are not at high risk for bleeding. In patients
that receive a bare metal stent (BMS), ACC/AHA recommends a minimum of one month of
clopidogrel, but also notes that it would be ideal to continue clopidogrel for 12 months (Antman
et al., 2008). Unfortunately, the cost for clopidogrel ranges from $5.60 to $6.10 per tablet at
local pharmacies and no generic preparation available. Uninsured or underinsured patiens
without financial resources sufficient to purchase these medications easily are at particularly high
risk for non-adherence.
In an effort to meet the CMS AMI indicators, a Central Florida tertiary care center
implemented a Code STEMI process in February 2006. This process focuses on early
recognition by the ED and rapid activation of and transport to the cardiac catheterization lab.
This ensures that patients having a STEMI are receiving the same quality care on an inpatient
basis regardless of financial status and ability to pay. While the intent of the core measures is to
provide the best care to all STEMI patients presenting to the hospital, they do not take into
consideration the ability of the patient to adhere to necessary follow up care. The component of
medication adherence post procedurally has been neglected in considering the care of these
patients.
4

Once the STEMI program was initiated at the facility, the number of Code STEMI’s
treated during the first year was obtained and noted to be 97 cases, an average of 8.1 cases per
month. Of these STEMI’s, 17 were identified as patients who were either uninsured or who
might have some difficulty paying for the clopidogrel.
Four of the 17 patients that underwent PCI during this period of time were readmitted to
the facility through the ED with subacute thrombosis in the recently implanted stent. All four of
these patients returned within 1 months of discharge. In all four cases the physicians
documented non-adherence with regards to clopidogrel. In other words, 23.5% of uninsured
patients were readmitted with subacute thrombosis as a result of being non-adherent to their antiplatelet regimen.

Objective/Aim
The main objective of this project is to evaluate outcomes of providing clopidogrel
(actual medication rather than a prescription that the patient will have to fill) to all uninsured
patients presenting to the tertiary care center with STEMI who receive BMS or DES as their
method of treatment. The assumption is that if the patient is provided with this very costly
medication, he/she will be more likely to adhere to the prescribed medication regimen.
Comparing three-month readmission rates for patients with STEMI will assess medication
adherence. The time period reviewed for initial presentation with STEMI will be from February
2009 to February 2010. Readmissions (repeat STEMI) will be reviewed for the time period
beginning February 2009 and ending May 2010 to ensure that 3-month readmission data are
captured.

5

Research Questions
1. Is there a difference in readmission rates between uninsured STEMI patients who receive
medication, actual “drug-in-hand”, and those who receive a prescription to fill?
2. Are uninsured patients who receive “drug-in-hand” less likely to be readmitted than
insured patients who receive a prescription to fill?

Definitions
For this project, terms are defined as follows:

Table 1: Project Definitions
Term
Subacute thrombosis

Adherence

Conceptual Definition
A partial or total stent
occlusion in the initial stent
as documented by
angiography (Iakovou,
2005).
Taking medications as
prescribed.

Medication provision

Patient will have “drug in
hand” (clopidogrel and
aspirin only) prior to
discharge.

True uninsured

Patients for whom no
evidence of insurance
coverage can be found.
Paper prescription for
clopidogrel that is given to
the patient.

Prescription
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Operational Definition
Documentation in
catheterization report by
interventional cardiologist.

No readmission within 3
months of initial AMI
assumes adherence
Documentation by the
Social Work Department
that medication was
provided to patient prior to
discharge.
Business office verification.

Patient discharge
assessment form, absent
documentation of
medication provision.

Assumptions
For the purposes of this project, the following assumptions are made:
1. Patients will take medication if it is provided to them
2. Medication adherence is assumed when a patient is not readmitted with repeat STEMI
within the study period.
3. Uninsured patients find it more difficult to afford medications.

Study Importance
The importance of this project revolves around patient outcomes. Patients that have a
STEMI are in a position to receive the best interventional care available. Unfortunately, this care
does not always ensure positive long-term outcomes.

This is, in part, due to the cost of

medication that is required to help ensure stent patency. If providing medication to patients
promotes medication adherence, a catastrophic cost to the patient, in addition to the burden on
the health care system and society, may be avoided.
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CHAPTER TWO: LITERATURE REVIEW
An integrative review of the literature was conducted to evaluate the concept of
adherence, specifically medication adherence. To begin the integrative review, the CINAHL and
PubMed databases were searched. Key words that were searched were adherence, medication,
clopidogrel and cardiac. The search of the electronic database was limited to English articles
from 2004 to 2010. The year limitation was chosen to obtain the most recent research pertaining
to medication adherence. Using the key words adherence and medication, 2,364 articles were
returned. Combining medication with adherence or compliance returned 592 articles. When the
terms cardiac and clopidogrel were added, 51 articles were returned. Of these 51 articles, 5
articles were an actual analysis of the concept of adherence. An additional 9 articles that
pertained directly to medication adherence in patients with diagnosed cardiac disease, with one
article specifically discussing adherence to clopidogrel, were included in the review (Figure 1).
Medication compliance was used in the search because it is frequently used interchangeably with
adherence. Antecedents that were identified in the search were compliance, concordance, and
non-adherence.
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Figure 1: Literature Search Results

The World Health Organization (WHO) defines adherence as “the extent to which a
person's behavior – taking medication, following a diet, and/or executing lifestyle changes,
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corresponds with agreed recommendations from a health-care provider.” Terms that have been
recognized as interchangeable with adherence include compliance and concordance (Rolley, et
al, 2008).
Compliance is a term that is not frequently used due to the negative connotation that it
carries (Shay, 2007, Bissonnette, 2008). The term compliance indicates an unequal relationship
between provider and patient due to the paternal undertones it carries (Bissonnette, 2008).
Compliance also refers to obedience, which detracts from a collaborative relationship with a
provider (Bissonnette, 2008). Different ways of viewing the term compliance within healthcare
have been identified and it is the way that it is viewed that determines the connotation. The three
ways of viewing compliance are evaluative, rationalization, and acceptance. When compliance
is viewed in an evaluative manner, patients may be seen as difficult if they are not compliant in
their therapies (Shay, 2007).

Adherence as a Concept
The WHO definition of adherence indicates a more collaborative relationship between
patient and provider. Another very common definition of adherence is how well the patient
follows a prescribed treatment regimen (Haynes, et al, 2005). Adherence is also considered to be
non-judgmental and is the preferred term when discussing patients’ health behaviors in relation
to prescribed medication therapies (Julius, et al, 2009). Poor adherence to prescribed medical
therapies increases mortality and morbidity in certain diagnoses (Wu, et al, 2008).
From adherence, there has been a gradual movement towards the term concordance,
which suggests a more participative relationship between patient and provider. Concordance also
suggests that a negotiation between patient and provider has led to an agreement suitable to both
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parties (Bissonnette, 2008, Lehane & McCarthy, 2009). However, there is currently limited
research related to concordance as an individual concept (Bissonnette, 2008). There is an
abundance of literature addressing concordance as a synonym for adherence.
Non-adherence is a concept that is used interchangeably with lack of, or poor adherence.
Non-adherence is recognized as a serious health issue. Recommendations have been made to
elevate the issue of non-adherence to a critical health care issue. Non-adherence leads to
increases in hospitalization, mortality and morbidity (Lehane & McCarthy, 2009, Wu, et al,
2008).

Barriers to Adherence
Factors affecting medication adherence fall into four areas: patient-related,
psychological, medication-related, and social/environmental. Patient related factors include age,
gender, marital status and ethnicity. Of more interest are the psychological risk factors, which
are denial of illness and negative attitudes about medications (Julius, et al, 2009). Negative
attitudes about medications are attributed to patient concerns about necessity and safety of
prescribed medications (Aikens & Piette, 2009).
Medication-related factors that contribute to non-adherence are side effects and dosing
schedules. More complex dosing schedules are associated with decreased adherence (Julius, et
al, 2009).
The other factors that influence medication adherence are social and environmental
factors. A collaborative or therapeutic relationship with a provider improves medication
adherence (Julius, et al, 2009). Socioeconomic status also contributes to adherence as
demonstrated by decreased adherence to lipid lowering agents when co-pays are increased

11

(Doshi, et al, 2009). A predictive study by Choudry, et al (2007) suggested that post AMI
patients that had no out-of-pocket costs for medications after hospitalizations would be more
adherent to medication regimens. Through medication adherence, a resultant cost savings was
predicted based on decreased rehospitalizations. Cost was also cited as a reason for not filling
prescriptions for clopidogrel by patients who had received a coronary stent. This is an example
of non-adherence that can lead to rehospitalization as discontinuation of clopidogrel by patients
with stent placement puts them at risk for in-stent thrombus formation (Jackevicius, et al, 2007).

Barriers to Adherence in the Cardiovascular Patient
Medication adherence in cardiovascular disorders is well documented. Heart failure is an
area where medication non-adherence has been shown to increase the risk of mortality and
morbidity as well as increase health costs (Wu, et al, 2008). Medication adherence is also linked
with self-efficacy. Schoenthaler, et al (2009) showed that self-efficacy mediates the relationship
between depression and adherence. It was noted that depressive symptoms led to medication
non-adherence. Depression in patients experiencing acute myocardial infarction (AMI) is
prevalent as seen by the number of prescriptions for antidepressants prescribed at discharge for
these patients (Jackevicius, et al, 2007).
Another area that contributes to decreased adherence in patients diagnosed with acute
coronary syndrome (ACS) was partner stress defined as stress or conflict within a relationship
(Molloy, et al, 2008). In this study, partner stress within six months prior to onset of ACS
predicted medication non-adherence.
Discharge medication counseling by pharmacists has been shown to improve medication
adherence and understanding. Interventions that occur at the time of an acute event have been
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shown to increase adherence to prescribed treatment therapies; therefore, discharge medication
counseling has the potential to improve long-term adherence. However, discussion of discharge
medication counseling has been inconsistent (Jackevicius, et al, 2007).
The most recent article addressing adherence in the cardiac patient was specific to
clopidogrel adherence. The focus of this article was prescription filling and delays associated
with filling. The authors identified factors associated with delays to include advanced age, prior
AMI, other comorbidities such as diabetes or renal failure, and in-hospital bleeding (Jackevicius,
et al, 2010). Cost as a barrier was not addressed. In this article the authors emphasized the
importance of transition care in patients that have DES implanted (see Table 2).
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Table 2: Summary Table
Authors/
Discipline
Methods
Year/
Country
Aikens, J.E. & Psychosocial Face to face interviews, Bayer
Piette, J.D.
2000 analyzer for HgbA1C, Omron
(2009)
automatic BP monitor with
appropriately sized cuff for BP
measurement

Bissonnette,
J.M. (2008)

Nursing

Evolutionary Method

Sample/Setting

806 type II diabetics on
antihyperglycemic and
antihypertensive
medications

Papers identified = 114:
Nursing – 27
Antecedents/Consequences/Related Psychology – 39
Concepts: A prescribed medication Medicine – 33
regimen is the primary antecedent. Pharmacy – 15
Consequences fall into 3 categories
– patient related, health care
Final sample:
professional related and health care Pharmacy – 8
system related. Related concepts
Psychology – 15
are therapeutic alliance, acceptance Medicine – 15
and agreement.
Nursing - 15
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Findings

Up to one half of patients
underused their medications as a
result of low health literacy, cost
of medications, perceived need
for medications, and fear of
harmfulness of medications.
Adherence was determined
through self-reporting
Findings by healthcare
discipline: Nursing uses
compliance and adherence.
Psychology uses compliance and
adherence interchangeably and
considers these a key component
of care. Medicine uses
adherence and compliance
synonymously. Pharmacy
mirrors the approach of
medicine.

Authors/
Discipline
Methods
Year/
Country
Choudhry, N. K., Medicine A Markov Model was created by
Avorn, J.,
the authors to evaluate cost and
Antman, E. M.,
quality-adjusted life expectancy to
Schneeweiss, S.,
post MI Medicare patients without
& Shrank, W. H.
any out of pocket costs. This was
(2007)
compared with current Medicare
part D coverage.

Doshi, J. A.,
Zhu, J., Lee, B.
Y., Kimmel, S.
E., & Volpp, K.
G. (2009)

Medicine

Fernandez, R.,
Davidson, P.,
Griffiths, R.,
Juergens, C., &
Salamonson, Y.
(2007)

Nursing

Sample/Setting

Results predicted that Medicare
patients that were under the
partial coverage plan would live
an average of 8.21 QALY and
incur costs of $114,000. Cost
savings was attributed to
decreased rehospitalizations and
decreased non-drug
expenditures.
Quasiexperimental study utilizing
5,604 patients receiving care Increase in co-payments
administrative data and electronic
at the Philadelphia VAMC
adversely affects adherence to
medical record information to
and filled at least one rx for lipid lowering agents among
compare changes in lipid lowering lipid lowering agent within a veterans. This was true even
medication use over time for
24 month period prior to
among veterans that were at high
veterans who experienced increases increase in copayments.
risk for coronary artery disease.
in prescription copayments vs.
veterans who did not.
Cross-sectional study utilizing a
270 subjects who underwent The authors found that patients
self-administered questionnaire
PCI between April 2003 and report high rates of adherence to
that was mailed to participants.
March 2004 and met
medication after PCI. Patients
Subjects were followed up to 12-24 inclusion criteria.
considered themselves to be
months following PCI.
adherent despite missing
medication dosages.
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No actual patients were
involved in this study. It
was a predictive study.

Findings

Authors/
Year/
Country
Jackevicius, C.
A., Li, P., & Tu,
J. V. (2008)

Discipline

Methods

Sample/Setting

Findings

Medicine

4,591 post MI patients with
12,832 discharge
prescriptions written

Of discharge Rx, 92.3% were for
cardiac medications. 59.5% had
< 10 prescriptions filled within
the 120 days. Only 74% of
patients filled all of their
prescriptions within 120 days.
Aspirin was not considered a
prescription and data regarding
taking aspirin were not collected.
10% of patients did not fill any
prescriptions.

Julius, R. J.,
Novitsky, M., J.,
& Dubin, W. R.
(2009)

Psych

Up to 125 charts from 104
hospitals in Ontario were
abstracted. Charts were identified
through the EFFECT Registry.
The Registry was linked to
prescription claims, demographics,
physician service and hospital
discharge. Non-Ontario residents
were excluded because the
investigators did not have access to
their prescription filling
information. Patients admitted to
long-term care facilities were
excluded.
Literature Review

Search using key words
“medication adherence” and
“compliance” = 2,000
references

Factors affecting medication
adherence were broken into four
areas: patient related,
psychological, medicationrelated and social/environmental.

After initial search articles
were limited regarding
psychiatric medications and
specific medication classes.
Also limited to articles
involving clinical focus.
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Interventional strategies:
psychoeducational, cognitivebehavioral therapy, and
motivational interviewing.

Authors/
Year/
Country
Lehane, E., &
McCarthy, G.
(2009)

Discipline

Nursing

Methods

Sample/Setting

Literature Review surrounding
medication adherence.

A critical synthesis of the
literature to determine key
attributes for adherence,
compliance, and
concordance.
26 papers were reviewed

Molloy, G. J.,
Psychology Prospective study design with
Perkins-Porras,
follow-up data collected for 12
L., Strike, P. C.,
months after hospital admission.
& Steptoe, A.
(2008)

Acute Coronary Syndrome
(ACS) patients – N = 193
Setting: 4 local London
hospitals
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Findings

The definition of adherence is
allocated into 5 categories –
coincidence of patient behavior
with professional advice,
relationship as part of the
process of care, outcome and
process targets, taking
medications as prescribed, and
other factors influencing
behavior.
The authors found that partner
stress predicted nonadherence.
Just under 30% of patients were
deemed to have poor adherence,
but the authors felt that this is
and underestimate because of the
influence of social desirability
biases. Patients with large social
networks were more likely to
attend rehab. Partner stress and
small social networks were
associated with poorer quality of
life.

Authors/
Year/
Country
Rolley, J.X.,
Davidson, P.M.,
Dennison, C.R.,
Ong, A., Everett,
B., &
Salamanson, Y.
(2008)

Discipline

Nursing

Methods

Sample/Setting

Integrative Literature Review

Schoenthaler, A., Psych
Ogedegbe, G., &
Allegrante, J. P.
(2009)

Cross-sectional study using Kenny
and Baron analytic framework of
mediation

Shay, L.E.
(2008)

Walker and Avant Framework

Nursing
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Search of electronic
databases – CINAHL,
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Findings

Medication adherence depends
on a range of physical, social,
economic and psychological
considerations. Methods of
assessing medication adherence
require further investigation.

Self-efficacy mediates the
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symptoms and medication
adherence, with the correlation
that depressive symptoms lead
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with medications.
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Findings

Adherence rates above 88%
were more sensitive and specific
to predicting better event free
survival (decreased number of
ED visits with increased
adherence to prescribed
medication regimen.

Summary
Adherence is the most commonly used term in healthcare to describe a patient’s
participation in their healthcare. Originally, compliance was the term that indicated a patient’s
participation in their healthcare, but due to the paternalistic tone of the term, healthcare has
adopted the term adherence. There are many factors that affect adherence including but not
limited to socioeconomic status, belief in the healthcare system and provider, depression, selfefficacy, and partner stress. Medication adherence has been shown to be imperative in
decreasing risk of mortality and morbidity, and preventing rehospitalization. The reviewed
studies demonstrate that medication adherence (adherence is assumed based on prescription fills
and refills) is critical to positive outcomes post stent placement.
Current studies have reviewed medication adherence and its relationship to mortality and
morbidity for the medications supported through evidence for treatment of MI. Many studies
have been conducted to explore the relationship between clopidogrel and stent patency. No
studies were found that explored the relationship of medication compliance and insurance status.
Cost as a factor in medication adherence must be considered and is the premise for this project.
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CHAPTER THREE: METHODS
Implementation of Project
As part of a quality improvement initiative, pre-test data were collected for the 15-month
time period between February 2006 and February 2007 for all patients with STEMI that
presented to the ED at ORMC. Readmission data were collected until May 2007 to provide 3month readmission statistics after the STEMI. A cost-benefit analysis (CBA) was performed
using these data and a policy was developed to provide clopidogrel to all patients with STEMI
that had received a BMS and were uninsured.
The CBA reviewed admissions and 3-month readmissions of uninsured STEMI patients
who had been treated with BMS. During this 15-month period of time 17 uninsured patients
were admitted with STEMI and treated with BMS. Of these, 4, or 23.5% were readmitted within
3 months of initial presentation. A fifth uninsured patient was readmitted during this time frame,
but was listed as “Medicaid pending” and was therefore excluded from analysis. The cause of
readmission for this was also repeat STEMI. The repeat STEMI cost the patient in terms of
health, and cost the organization in terms of finances. Neither the initial hospitalizations for the
17 patients, nor the rehospitalizations for the 4 patients were reimbursed. The direct cost of
readmissions was approximately $36,700 or an average of $9,175 per patient.
The cost of providing clopidogrel for future uninsured STEMI patients was calculated by
projecting a 15% increase in number of uninsured STEMI’s presenting to the ER for the next
year. The projected cost of providing the additional 21-days of clopidogrel (Social Work
Department was already providing 7-days of clopidogrel) to the projected 20 patients was
calculated to be $720.

21

Assuming a 23% readmission rate for the projected STEMI patients if no clopidogrel is
provided, a 50% reduction in readmissions (2.5 less readmissions) with clopidogrel provision
would save the organization about $22,937.
Based on the results of the CBA, a policy was developed to provide 28-days of
clopidogrel to uninsured STEMI patients who are treated with BMS. This policy has slowly
been adapted to include uninsured STEMI patients who are treated with DES, and any STEMI
patient who does not have prescription insurance.

Design
The design for this study was a retrospective chart review in a pre and post-test type
format. The phenomenon being studied is readmission post-stent placement for STEMI with
subacute thrombosis to the initial stented artery. This is not a case-control design, but is to study
project outcomes (Polit & Beck, 2008).
The major strength of this study design was that all patients were included. One
limitation of the study was that discharge education may vary by provider and since data will be
reviewed retrospectively with no exclusion criteria patient understanding of the importance of
taking clopidogrel post stent placement was unknown. Another limitation was that patients with
prescription insurance were not reviewed for compliance. An assumption was made that these
patients were filling their prescriptions. This was considered a limitation because the amount of
a patient’s co-pay may have been too high for the patient to afford and still prevented the patients
from acquiring the needed medication. There is new literature that demonstrates that some
patients are non-responders to clopidogrel. The testing that can identify these patients was not
being used at this organization, therefore this was another limitation of this study.
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Variables
The independent variable (IV) was the method provision of 28 days of clopidogrel prior
to discharge or provision of prescription prior to discharge with the expectation that the patient
will fill the prescription. Level of measurement for these variables was nominal. Demographic
data included gender (nominal), insurance status (nominal), type of insurance (nominal), patient
age (ratio/scale), and type of stent (nominal).
The dependent variable (DV) was rehospitalization for AMI resultant of subacute
thrombosis in the previously stented culprit vessel. This variable was also nominal level data.

Setting/Subjects/Sampling
This project was conducted at a tertiary care center in Central Florida. Subjects for the
pre-test data collection were all patients with STEMI that presented to the center’s ED from
February 2006, prior to the implementation of the clopidogrel provision policy, until February
2007, and for the three months following or until May 2007. Subjects for post-test data
collection were all patients with STEMI that presented to the center’s ED from February 2009,
the time the clopidogrel provision policy was initiated, until February 2010, and for the three
months following or until May 2010. No patients were excluded from the data collection process,
although the focus was on patients who are uninsured and therefore have a more difficult time
obtaining prescriptions (an assumption of the project). An exclusion criteria for the project was
insurance. If patients had insurance, they did not receive medication at discharge, only a
prescription.
Based on preliminary assessment, it was estimated that 200 subjects or records will meet
inclusion criteria for the two periods. Computing chi-square statistics, this sample size will
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detect an effect size of .20, alpha of .05, at a power of .80. A sample size of 220 was requested
from the IRB to ensure that data from all eligible subjects during the two time periods was
retrieved for analysis.
Patient charts are coded after discharge by the Coding and Billing Department at the
Center. Coding identifies all patients that had an STEMI. The Quality Department reviews all
patient charts for those patients who had STEMI to determine whether or not the core measures
were met. Quality is able to query all medical record (MR) numbers for patients with STEMI
during a specified period of time. Since MR numbers are unique to each patient, they can also be
used to access readmission information. MR numbers provided access to charts. Physician
documentation and cardiac catheterization results were reviewed, as well as discharge
instructions.

Human Subjects
The benefits of clopidogrel post-stenting are well documented throughout the research,
and the ACC/AHA recommendation are that all patients receiving coronary stents should take
clopidogrel for time periods determined by the type of stent they received (Faxon, 2007). Since
all patients treated with stents for STEMI receive a prescription for clopidogrel at discharge,
there was minimal risk to the patient in this project. The difference in treatment for subjects
included in the study was that these patients received actual medication rather than a
prescription.
Approval was requested from the Institutional Review Boards (IRB) at the University of
Central Florida (UCF) and at the Center (Appendix B). The potential risk to the subjects was the
possibility of a breach of confidentiality. Health Insurance Portability and Accountability Act
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(HIPAA) guidelines were followed to prevent a breach of confidentiality. Each chart reviewed
was assigned a unique identification number that did not have any association with the medical
record number. The log with these numbers was kept by the primary researcher in a locked file
cabinet. At the completion of the study, this information was destroyed by shredding. This
information was not shared or reused by anyone except as required by law or the IRB’s.
A waiver of consent was requested and a HIPAA Waiver Authorization Form was
submitted to the IRB’s. Additionally, the HIPAA De-identification form was also be submitted.

Instruments/Data Collection Tool
An Excel spreadsheet was used to collect data (Appendix B). This tool was constructed
for the purposes of this study. Data included gender, age, insurance, type of stent, vessel stented,
whether or not the patient was readmitted, if readmitted for AMI which vessel was the cause,
clopidogrel prescription or medication provided, and physician documentation of non-adherence.
Sovera, a system which houses all patient permanent records for Center was used to obtain the
data. Patients were identified by the Quality Department at the Center.
The current policy to provide clopidogrel to all uninsured STEMI patients who receive
stents will continue. The data from the first time period was compared to the time period of 15
months after the clopidogrel provision policy began.
In addition to other documentation (physician documentation and cardiac catheterization
results) reviewed, the Social Work note was included in the second data set to determine if
eligible patients received their 28-days of clopidogrel prior to discharge. Excel was chosen for
the ease of export to SPSS. Direct export also decreased the chance of transcription errors.
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Procedures
Medication adherence was evaluated based on 3-month readmission rates and physician
documentation. The conceptual definition for adherence is taken from Jackevicius, et al who
defined adherence as filling and refilling prescriptions. (Jackevicius, Li, & Tu, 2008)
Prescription fills and refills were not measured in this project because the patients of primary
interest were those without insurance and there was no way to track fills and refills.
This project involved data collection prior to implementation of the clopidogrel provision
policy (Appendix A) and for the time period of fifteen months (so that readmissions may be
tracked for 3 months after stent placement) after implementation of the policy. Readmissions for
the 3 months after stent placement for STEMI were reviewed.
All charts for patients admitted with STEMI were reviewed. Data collected included age,
gender, insurance status, vessel stented, type of stent placed, and if patient was readmitted.
Readmitted patient charts were reviewed to determine if the readmission was as a result of an
AMI caused by subacute thrombosis. Physician documentation was reviewed for documentation
of clopidogrel non-adherence and Social Work documentation was reviewed to ensure that
clopidogrel was provided to patient prior to previous discharge. These results were compared to
the data collected for the 15 month time period prior to implementation of the clopidogrel
provision policy.
Once all data were collected, data were imported into the SPSS 16.0 statistical package
(Chicago, IL) for data analysis.
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Data Collection Tool
In addition to other documentation (physician documentation and cardiac catheterization
results) reviewed, the Social Work note was included in the second data set to determine if
eligible patients received their 28-days of clopidogrel prior to discharge. Excel was chosen for
the ease of export to SPSS. Direct export also decreased the chance of transcription errors. The
data collection tool used was developed to be specific to this study and to capture the required
variables, therefore there was no reliability or validity data for this tool. (Appendix B)

Data Analysis
Since all data with the exception of age are nominal, non-parametric tests were conducted
(Munro, 2005). For this project, chi-square/crosstabs analysis will be done. Another reason for
choosing non-parametric tests was because the assumption of normal distribution is not required
for these tests. The assumptions of independent categories, levels of measurement, and
theoretical reasons for categories were made (Munro, 2005). The data to be collected was
predetermined. Chi-square/crosstabs was used to compare readmissions by those insured versus
those uninsured. It was also used to compare readmissions prior to implementation of the
clopidogrel provision policy with readmissions occurring after the policy was in place.
Readmissions were also compared by age group and insurance status, as well as gender and
insurance status.
The primary research questions and data analyses were as follows:
1. Is there a difference in readmission rates between uninsured STEMI patients who
receive medication, actual “drug-in-hand”, and those who receive a prescription to
fill? – chi square/crosstabs analysis
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2. Are uninsured patients who receive “drug-in-hand” less likely to be readmitted than
insured patients who receive a prescription to fill? – chi square/crosstabs analysis

The a priori alpha level testing for the research questions is .05.

Limitations
A major limitation of this project was the inability to identify patients readmitted outside
of this hospital system. Another limitation of the study was that discharge education may vary by
provider. Since data was reviewed retrospectively with no exclusion criteria, patient
understanding of the importance of taking clopidogrel post-stent placement may not have been
consistent.

Summary
The goal of this project was to determine the effectiveness of providing clopidogrel to
STEMI patients treated with stents in decreasing readmissions with repeat AMI. AMIs result in
cardiac compromise and increased mortality and morbidity in patients with cardiac disease. If
readmissions can be reduced, the financial impact will be examined. This data will be presented
to the Department of Cardiology, Interventional Cardiology Collaborative Practice Team and
Administration to determine if the policy to provide clopidogrel is beneficial and should be
continued.
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CHAPTER FOUR: RESULTS
Study results are discussed in this chapter. Data are organized by demographics followed
by the research questions. Additional findings are also summarized.

Demographics
Demographics and statistical results of the retrospective chart review are discussed in this
chapter. Statistical analyses were performed using the SPSS 16.0 statistical computer program.
Data were analyzed using Chi square cross tabulation and T-test for independent samples. The
study sample for the pre-test group for this project included all patients presenting with STEMI
from February 2006 to February 2007, and for the 3 months following to assess for readmission.
The post-test group included all patients presenting with STEMI from February 2008 to February
2009, and for the 3 months following to assess for readmission.
Two hundred and one patients (n=201) were eligible for inclusion. One patient in the
post-test group was excluded because the medical record number could not be found in either of
the electronic medical records. A total of 200 charts were reviewed; 100 from the pre-test group
and 101 from the post test group. A summary of demographic characteristics is provided in Table
3. Demographic characteristics of age, gender and insurance status were not statistically
different between groups. The mean age for the control group was 59.1 (+ 13.8) and the mean
age for the post-intervention group was 58.9 (+ 13.6).
Although no significant differences were noted in the vessel stented between groups, a
significant difference in type of stent placed was noted. In the pre-test group, 19% of patients
admitted with STEMI were treated with (bare metal stents) BMS. In the post test group, 61.4%
were treated with BMS (p < .001).
29

Table 3: Demographics

Variable

Gender
Male
Female
Insurance Status
Uninsured
Medicare/
Medicaid
Commercial
Medicare +
Commercial
Type of Stent
Bare Metal

Variable

Type of stent
Drug-eluting
Vessel Stented
LAD
RCA
Cx
PDA
OM1
OM2
SVG
LIMA

Before
Clopidogrel
(Control)
N (%)

Group
After
Clopidogrel
(Intervention)
N (%)

All

p-value

N (%)
.558

74 (74.0%)
26 (46.4%)

71 (70.3%)
30 (53.6%)

145 (72.1%)
56 (27.9%)
.343

21 (21.0%)
30 (30.0%)

20 (19.8%)
37 (36.6%)

41 (20.4%)
67 (33.3%)

39 (39.0%)
10 (10.0%)

40 (39.6%)
4 (4.0%)

79 (39.3%)
14 (7.0%)
< .001

19 (21.3%)
Before
Clopidogrel
(Control)
N (%)

62 (67.4%)
Group
After
Clopidogrel
(Intervention)
N (%)

81 (44.8%)
All

p-value

N (%)

70 (78.7%)

30 (32.6%)

100 (55.2%)

39 (43.8%)
34 (38.2%)
10 (11.2%)
0 (0.0%)
1 (1.1%)
1 (1.1%)
3 (3.4%)
1 (1.1%)

35 (37.6%)
44 (47.3%)
7 (7.5%)
2 (2.2%)
3 (3.2%)
0 (0.0%)
2 (2.2%)
0 (0.0%)

74 (40.7%)
78 (42.9%)
17 (9.3%)
2 (1.1%)
4 (2.2%)
1 (0.5%)
5 (2.7%)
1 (0.5%)

.414

Legend vessel: LAD – left anterior descending, RCA – right coronary artery, Cx – circumflex, PDA – posterior
descending artery (a branch of the RCA), OM1 – obtuse marginal 1, OM2 – obtuse marginal 2, SVG – saphenous
vein graft, LIMA – left internal mammary artery
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Readmissions
The first objective of this project was to examine readmission rates in uninsured patients
who experienced and were treated for STEMI, to determine if those who receive medication in
hand were less likely to be readmitted than those who simply received a prescription.
The number of readmissions was not statistically different between groups (n = 5, 23.8%
control and n = 2, 9.1% intervention) However, the number of patients admitted with STEMI
was more than double during the control period versus the intervention. The goal of this project
was to reduce STEMI readmissions, particularly in the uninsured population. Five uninsured
patients (23.8% of readmissions) in the control group were readmitted with STEMI. In the post
intervention group 2 uninsured patients (9.1% of readmissions) were admitted with STEMI.
This was not statistically significant (p = .191) most likely due to the small sample size (N = 43).
Additionally, all readmissions for STEMI patients in the control group occurred within 30 days
while both readmissions in the post intervention group occurred within 31-60 days. This was a
statistically significant finding (p = .008). Findings are summarized in Table 4.
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Table 4: Readmission of Patients (n = 43)

Readmit

Cause
STEMI
Other
Time to Readmission
< 30 days
31-60 days

Group
After
Clopidogrel
(Intervention)
N (%)

Before
Clopidogrel
(Control)
N (%)

All

p-value

N (%)
.191

5 (23.8%)
16 (76.2%)

2 (9.1%)
20 (90.9%)

7 (16.3%)
36 (83.7%)
.008

5 (100.0%)
0 (0.0%)

0 (0.0%)
2 (100.0%)

5 (71.4%)
2 (28.6%)

Legend: STEMI – ST-elevation myocardial infarction

The second objective of this project was to determine if patients that received drug in
hand were less likely to be readmitted with STEMI than patients who received a prescription.
All STEMI readmissions from both groups were uninsured patients (N = 7). There were no
STEMI readmissions in insured patients during the study time frame.

Additional Findings
STEMI readmissions were analyzed by adherence to prescribed medication regimen,
specific to clopidogrel because readmission as a result of subacute thrombus formation occurs
with non-adherence to prescribed antiplatelet agents. Uninsured patients in the pre-test group
were provided with a prescription for clopidogrel. Uninsured patients in the post-test group were
to be provided with clopidogrel rather than a prescription. Therefore, adherence to clopidogrel
and provision of clopidogrel in the post-test group (n = 13) and were analyzed using cross tabs
Chi-square. All patients (n = 7) that were readmitted with STEMI had physician documentation
of clopidogrel non-adherence. Thirteen (13) patients met criteria for clopidogrel provision. Of
these, 8 patients (61.5%) received clopidogrel and 5 (38.5%) did not. This was a clinically
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significant but not statistically significant finding. Reasons for not getting the clopidogrel
included being transferred to a telemetry unit other than the existing post interventional unit,
leaving against medical advice and having an existing prescription for clopidogrel with
documented medication adherence.

Table 5: Medication Adherence by MD Documentation

Variable

Adherent
No
Yes
Clopidogrel
Provided
Yes
No

Before
Clopidogrel
(Control)
N (%)

Group
After
Clopidogrel
(Intervention)
N (%)

All

p-value

N (%)

5 (100.0%)
0 (0.0%)

2 (100.0%)
0 (0.0%)

7 (100%)
0 (0.0%)

N/A
N/A

8 (61.5%)
5 (38.5%)

8 (61.5%)
5 (38.5%)

Findings were presented in this chapter. The last chapter discusses interpretation of
findings.
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CHAPTER FIVE: CONCLUSION

This chapter discusses findings, limitations, conclusions and implications for nursing
practice of the study as related to the study questions. Recommendations for future research
related to the outcomes of this study are also discussed.

Discussion
The main objective of this study was to evaluate outcomes of providing clopidogrel to
uninsured patients presenting with STEMI who were treated with intervention utilizing BMS or
DES. The first research question posed to evaluate these outcomes was “Is there a difference in
readmission rates between uninsured STEMI patients who receive medication, actual ‘drug-inhand’, and those who receive a prescription to fill?” To answer this question, readmission rates
were compared between STEMI patients before and after implementation of a program that
provided clopidogrel to uninsured patients.
All-cause readmission rates were similar between groups with 21.9% of STEMI patients
being readmitted in the pre-test group and 23.0% being readmitted in the post-test group (p =
0.85). However, a reduction in readmission rates due to subacute thrombus formation leading to
STEMI was noted between groups, with 5 uninsured patients being readmitted in the pre-test
group and only 2 uninsured patients in the post-test group. However, this was not a statistically
significant finding (p = 0.191), most likely related to the small sample size (n = 43). The finding
is clinically significant (23.8% of readmissions in the pre-test group vs. 9.1% in the post-test
group).
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“Subacute thrombus” is the term to describe stent thrombosis which occurs in the first 30
days after stent implantation. (Grines et al., 2007) By providing the first 30-days worth of
clopidogrel to uninsured patients, the liklihood of adherence was increased by removing barriers
to obtain medication and therefore may be related to the decrease in readmissions as a result of
subacute thrombus formation. This finding is supported by Rolley, et al (2008) who found that
medication adherence depends on many factors, including social and economic considerations.
By providing uninsured patients with medication economic status was taken into consideration
and removed as a barrier. Additionally, increased education to STEMI patients regarding the
importance of taking their clopidogrel as prescribed may have increased adherence, at least in the
first month after discharge. A limitation is that factors related to adherence were not directly
assessed.
In addition to a reduction in readmission rates, length of time to STEMI readmission was
evaluated. In the pre-test group, all STEMI readmissions occurred within 30 days of discharge.
In the post-test group, STEMI readmissions did not occur within the first 30 days, but in days 3160. This was a both a statistical (p = .008) and clinically significant finding. Patients in the posttest group who were treated with BMS and met criteria were provided with 28-days of
clopidogrel at the time of discharge therefore the patients would have completed their course of
clopidogrel by the time of their readmission. This finding is supported by Ho, et al (2008) who
found an increase in adverse events in the first 90 days after discontinuation of clopidogrel in
patients who had been treated with PCI (Ho et al., 2008), since the two readmissions in the
intervention group occurred within 31 to 60 days which began the time period after completing
their 30-day course of clopidogrel.
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The second research question was “Are uninsured patients who receive ‘drug-in-hand’
less likely to be readmitted with repeat STEMI than insured patients who receive a prescription
to fill?” To answer this question readmissions were compared by insurance status and by reason
for readmission. Both patients who were readmitted with STEMI were uninsured. Insured
patients were readmitted for other reasons to include elective surgery, elective staged PCI,
congestive heart failure, etc. It should be noted that more uninsured than insured patients were
readmitted with STEMI from both groups. This was a statistically significant finding (p = .012).
This may be due to the lower cost of clopidogrel for patients with insurance, thereby allowing
them to continue clopidogrel for a longer period as recommended by the guidelines. It is ideal
for patients treated with BMS to take clopidogrel for at least 6 months after stent implantation
(Antman et al., 2008)and uninsured patients may not be able to afford clopidogrel after the first
month’s supply.
Patients who met criteria for clopidogrel provision were evaluated to determine if all
eligible patients received the medication. It was found that only 8 of 13 (61.5%) received
medication. Five (38.5%) patients did not receive their medication at discharge. This was not a
statistically significant finding, but is clearly clinically significant as five patients who were
supposed to receive the clopidogrel per protocol to did not receive their medication. Upon
analysis, this finding can be attributed to patient location (unit) at time of discharge. The tertiary
center where this study was conducted has a designated unit for post-PCI patients, both elective
and those treated for STEMI. Some STEMI patients are admitted to the Coronary Care Unit
(CCU) immediately following their intervention and then transferred to a telemetry unit. Bed
availability occasionally causes these patients to be transferred to monitored units other than the
designated post-PCI unit. Of the patients that did not receive their clopidogrel, one was already
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taking it, one left against medical advice and the other three were discharged from telemetry
units other than the post-intervention unit. Therefore, they did not receive the same evaluation
by Social Work as those patients on the post-intervention unit. Additional systems/procedures
are needed to ensure that all eligible patients receive the medication as indicated.
Answering the second question assumes that patients who receive medication will be
adherent. Therefore, every STEMI readmission was evaluated for adherence to medication
based on physician documentation. All STEMI readmissions, both pre-test and post-test, had
physician documentation of non-adherence to clopidogrel.

Additional Findings
The intervention to provide 28 days of clopidogrel to uninsured STEMI patients (patients
received 2 days of clopidogrel while hospitalized) was based on the ACC/AHA guidelines which
recommend a minimum of 30 days of clopidogrel to prevent subacute thrombus formation with
BMS.(Antman et al., 2008) At the time of project implementation interventional cardiologists
involved with the Code STEMI process were educated to the criteria for clopidogrel provision
and to consult Social Work for any patients that met the criteria.
It is believed that as a result of this project and related physician education (all
interventional cardiologists taking STEMI call were individually educated by the principal
investigator), a change in practices for treatment of STEMI occurred. Prior to the intervention,
19 (21.3%) of patients were treated with a BMS. After the intervention, 62 (76.5%) patients were
treated with a BMS, (p = < .001). This practice change occurred despite insurance status. The
STEMI process in place at the Center allows 25 minutes from time of presentation to the ED to
transfer to cardiac catheterization laboratory. This time constraint and the urgency of the

37

situation decreases the opportunity to accurately assess for ability to be adherent. It was not
sufficient to identify whether or not a patient had insurance, as insurance co-pays and limitations
with Medicare prescription coverage can lead to barriers with adherence. Since the ACC/AHA
guidelines for clopidogrel therapy with BMS recommend a minimum of 30 days, (Antman et al.,
2008) socioeconomic barriers to adherence (Rolley et al., 2008) were decreased for insured
patients treated with a BMS with this change in practice. It’s important to note that while the
ACC/AHA guidelines for clopidogrel therapy with a BMS recommend a minimum of 30 days,
the guidelines also state it would be ideal if clopidogrel therapy could be continued for up to 12
months. While the socioeconomic barriers to obtaining the initial 28-days of clopidogrel were
decreased, these barriers were not removed and patients were not able to continue the
recommended ideal therapy.

Limitations
The major limitation of this study was the inability to identify patients that may have
been readmitted with STEMI to a hospital not within the study site’s healthcare system. Another
limitation of the study is the small sample size, particularly in the evaluation of STEMI
readmissions.
Lack of utilization of the dedicated unit for post-PCI patients was another limitation. This
resulted in some patients that met criteria for clopidogrel provision not receiving their
medication. This may have contributed to the two STEMI readmissions. However, is also
identified the need to modify procedures to ensure that all eligible patients receive the
medication. Additionally, the nursing staff and nurse practitioner on the dedicated unit provided
uniform education on the importance of medication adherence, specific to clopidogrel, to all
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patients. Patients admitted to other units may or may not have received the same education,
resulting in varying understanding of the importance of medication adherence.

Implications for Nursing Practice
This study evaluated a process improvement project implemented to reduce readmissions
as a result of subacute thrombus formation in STEMI patients by meeting the ACC/AHA
guidelines (Antman et al., 2008) for anti-platelet regimens in patients being treated with stents
for STEMI. This project was a collaborative effort between the coordinating nurse practitioner,
interventional cardiologists, Social Work Department, outpatient pharmacy and nursing staff,
with each department having a specific role. The goal of the project was to improve medication
adherence in the uninsured STEMI population by providing clopidogrel “drug-in-hand” and
thereby eliminate barriers to obtaining the medication. However, patient evaluation for type of
stent and education regarding the importance of adherence to clopidogrel were imperative to the
success of the program. These points could not have been addressed without collaboration from
all departments. As a result of this project, the outpatient pharmacy has added a pharmacy tech
to deliver the medications to the bedside, eliminating the need for the Social Worker to travel to
the pharmacy to obtain the medication.
The education regarding medication adherence provided by the nursing staff was
consistent for all PCI patients on the designated unit. Nursing was also instrumental in
identifying patients that met criteria for clopidogrel provision when a Social Work consult had
not been entered. The study also made the nurses more aware of the socioeconomic needs of
patients.
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For the purposes of this project, the coordinating nurse practitioner also collaborated with
Sanofi-Aventis and Bristol Myers Squibb, the pharmaceutical agencies that co-market
clopidogrel. As part of their marketing program, both companies provide vouchers for 14 free
days of clopidogrel for patients receiving new prescriptions for the medication. Through this
collaboration, the acute care hospital in Central Florida received more of these vouchers than any
other site in the country. The redemption rate for these vouchers, as tracked by these companies,
is higher in the Central Florida area than in any other area in the country (approximately 80%
redemption versus approximately 14%). These vouchers were used in conjunction with the
Social Work department’s resources to provide medication for these patients. Since the
completion of this project the policy has been revised to provide 30 days of clopidogrel to any
patient presenting to the Emergency Department at the facility who is treated with a BMS, and
has no insurance, no prescription coverage, or whose Medicare prescription benefits have
expired.
Resources exist that would allow this policy to be adapted in other facilities. Multidisciplinary collaboration that is physician and advanced practice nurse led is integral to
implementing this type of project. Increased utilization of electronic medical records requires
that information technology be included in the planning stages to assist in identifying these
patients prior to discharge.

Recommendations for Further Research
One of the issues that was identified with this study was providing medication to all
uninsured STEMI patients that met criteria. This occurred due to patients being transferred to
telemetry units other than the designated post-PCI unit. A prospective study that identified
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patients at time of STEMI admission and enrolled them would allow for a more controlled study
and ensure that all eligible patients receive medication prior to discharge.
Prescription co-pays and restrictions with Medicare coverage have proven to be barriers
in obtaining medication. The program should be expanded to evaluate the socioeconomic needs
of any STEMI patient regardless of insurance status to determine if the patient can reasonably
afford his/her medication, providing medication to those whose socioeconomic status creates a
barrier to acquiring clopidogrel. Further research could then be conducted to determine if
supplying the initial month of clopidogrel improves adherence and decreases readmissions.
Since the inception of this study a new anti-platelet agent, prasugrel, has been approved
for use. Future studies might compare readmission rates between patients prescribed clopidogrel
versus those prescribed prasugrel. Consistent education and identification of patients would be
necessary for both groups.

Conclusions
This study evaluated the benefit of providing clopidogrel to uninsured STEMI patients
who were treated with a BMS. The pre-test group showed a 23.8% readmission rate with
uninsured STEMI patients. The post-test group showed a 9.1% readmission rate. The cost of
providing the clopidogrel to the 8 patients that received it was $297.92, compared to average
direct cost of one STEMI readmission which was $9,175.00, demonstrating a cost savings just
under $27,000.00. The medication in addition to the focused education each patient received
may have contributed to this reduction in readmissions.
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Additionally, a transition to increased use of BMS (21.3% vs. 67.4%) in STEMI patients
was noted in the post-test group. This was most likely a result of increased physician awareness
of barriers to adherence.
This program should be continued with increased focus on ensuring that patients are
placed on the appropriate unit. Additionally, other vulnerable populations should be considered
for inclusion in the program.
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APPENDIX A: PLAVIX PROVISION FOR INDIGENT CODE STEMI STENT
RECIPIENTS
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There are three criteria a patient must meet in order to qualify for 28 days of Plavix. The
patient must be a Code STEMI, uninsured and the recipient of a stent. The stent can be either
Bare Metal (BMS) or Drug Eluting (DES). In addition, a patient will qualify if they have
insurance without prescription coverage. They must still be a Code STEMI and the recipient of a
stent.
The process is as follows:
1)

Social Work/Case Management Tech identifies the Code STEMI patients who have
received a stent and is self pay status or without prescription coverage.

2)

Two scripts are needed, both for 14 days. The ARNP may be able to assist with
writing the scripts if the doctor is not available.

3)

SW/CMT must complete the Walgreens referral process for fourteen days of Plavix
then take the referral, a fourteen day trial card and the two scripts to OHScripts to be
processed. The trial card can be obtained from ARNP Sita Price on 5B/Cang or
Carolyn La Londe. SW/CMT later delivers the medication to the patient at bedside.

4)

The unit pharmacist needs to be informed that one of these patients has been
identified so that they can provide a bottle of aspirin. A copy of the script will need to
be provided to the pharmacist.

5)

SW/CMT should also provide the patient with a patient assistance program packet
which can be obtained through the Needymeds website.

6)

If an uninsured patient is going to be on Plavix for any length of time this is a good
indication that an OCMC referral would be appropriate.
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7)

**Weekends/Holidays: The patient will have to take the Walgreens referral, 14 day
trial card and scripts to Walgreens for processing. A 14 day trial card will be kept in
Team Leader’s (Dari) mailbox.

If you should have any questions about the process please contact:

Sita Price, ARNP 321-841-5168
Carolyn La Londe, MSW 321-841-5168 or 407-980-6037
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APPENDIX B: DATA COLLECTION TOOL
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Variables

Codes

ID
Age
Gender

1 = Male

2 = Female

Insurance

1 = Uninsured
0 = N/A

3 = Commercial
Insurance
2 = PCI/No Stent

4 = Medicare +
Commercial
3 = CABG

5 = Not
Available

Type of Intervention

2 = Medicare/
Medicaid
1 = Stent

Vessel_Stent

1 = LAD

2 = RCA

3 = Circ

4 = OM1

5 = OM2

Type_Stent

1 = BMS

2 = DES

3 = Not Available

Readmit_STEMI

0 = No

1 = Yes

2 = Not Available

Cause of Readmission

0 = N/A

1 = STEMI/MI

2 = Other

Time to Readmit

0 = N/A

2 = Within 90 days

Thrombus

0 = No

1 = Within 30
Days
1 = Yes

MD Documentation of
Non-adherence
Plavix Provided

0 = No

1 = Yes

0 = No

1 = Yes

3 = Not
Documented
2 = N/A (insured)

Adherence, if
Readmitted
LOS if Readmitted

0 = No

1 = Yes

2 = N/A

3 = Not
Documented
3 = Not Available

# of Days

0 = N/A

Discharge Disposition

1 = Home

2 = SNF

3 = ALF

4 = Expired

3 = Not Available

2 = Not Available
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5 = Not
Available

6 = PDA

7 = SVG

8 = LIMA

APPENDIX C: UCF IRB
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APPENDIX D: ORMC IRB
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